Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Torrent Pharma recalls...

    Torrent Pharma recalls over 8.82 lakh bottles of Losartan Potassium tablets from US, Puerto Rico

    Farhat NasimWritten by Farhat Nasim Published On 2019-05-13T10:00:52+05:30  |  Updated On 13 May 2019 10:00 AM IST
    Torrent Pharma recalls over 8.82 lakh bottles of Losartan Potassium tablets from US, Puerto Rico

    The company is recalling 3,31,764 bottles of Losartan Potassium and Hydrochlorothiazide tablets, USP, 50mg/12.5mg from the US and Puerto Rico, the report said.


    New Delhi: Drug firm Torrent Pharma Inc is recalling over 8.82 lakh bottles of Losartan Potassium tablets, used for the treatment of hypertension, from the US and Puerto Rico markets on account of deviations from the current good manufacturing norms, according to a report of the US health regulator.


    The US-based arm of Torrent Pharmaceuticals is recalling 28,464 bottles of Losartan Potassium tablets USP in the strength of 25 mg manufactured by the parent company at its Indrad facility in Mehsana district, the latest Enforcement Report of the United States Food and Drug Administration (USFDA) said.


    Read Also: Torrent Pharma gets certain USFDA observations for Indrad plant


    The company is also recalling 164,424 bottles of Losartan Potassium tablets, USP, 50 mg from the US and Puerto Rico, the regulator said.


    Torrent Pharma Inc is also recalling 65,184 bottles of Losartan Potassium tablets, USP, 100 mg from these markets, it added.


    The company is recalling 3,31,764 bottles of Losartan Potassium and Hydrochlorothiazide tablets, USP, 50mg/12.5mg from the US and Puerto Rico, the report said.


    As many as 54,084 bottles of Losartan Potassium and Hydrochlorothiazide tablets, USP, 100mg/12.5mg, are also being recalled from these markets, it added.


    Read Also: Torrent Pharma recalls over 10.78 lakh bottles of Losartan citing CGMP deviations


    Torrent Pharma Inc is also recalling 2,39,016 bottles of Losartan Potassium and Hydrochlorothiazide tablets, USP, 100mg/25mg from the US and Puerto Rico.


    All the ongoing voluntary recalls of the hypertension treatment drug are class II recalls, it added.


    The reason for the recalls is "CGMP Deviations: FDA lab confirmed the presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million", the report said.


    Read Also: Torrent Pharma gets USFDA observations for Dahej plant


    CGMP refers to the Current Good Manufacturing Practice regulations enforced by the USFDA.


    As per the USFDA, a class II recall is initiated in a situation "in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote"

    CGMP DeviationsDrug firm Torrent PharmaFDAHydrochlorothiazide tabletshypertension drugLosartanlosartan potassiumLosartan Potassium TabletsNew DelhiPuerto RicoTorrent PharmatreatmentUnited StatesUnited States Food and Drug AdministrationUS health regulatorUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok